European Psychiatry - Volume 41 - April 2017

659 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S645–S709 S655
R. Martín Gutiérrez . Pérez Santos
B. Fernández-Abascal Puente
1 Hospital Universitario Marqués de Valdecilla, Psychiatry,
Santander, Spain
2 Hospital Universitario de Álava-Sede Santiago, Psychiatry,
Victoria-Gasteiz, Spain
3 Hospital Universitario Marqués de Valdecilla, General Medicine,
Santander, Spain
∗ Corresponding author.
Introduction Twenty percent of people aged over 80 have a
serious dementia. Cognition disturbances are present both in
depressive disorder and dementia. Vortioxetine is a new antide-
pressant with a multi-modal mechanism of action, being one of the
antidepressant with more procholinergic action.
Aims to know the efficacy of vortioxetine in elder people with
cognitive disturbances due to both pathologies: depression and
dementia.
Methods It is described the result of using vortioxetine in one
elder woman with dementia and affective symptoms with no clin-
ical improvement after using two classical antidepressants.
Results Woman aged 82 without psychiatric history came to our
consultation in April 2016. She had been diagnosed with demen-
tia last year by a neurologist and she had started treatment with
Donepezile 10mg/d. Six months after this diagnosis she com-
plained of depressivemood and faster deterioration of her previous
cognition disturbances in terms of functionality level and auton-
omy, so her neurologist prescribed escitalopram until 10mg/d
and mirtazapine until 30mg/d without clinical improvement. After
first exploration, we decided starting treatment with vortioxetine
10mg/d and withdraw previous antidepressants. Next week she
complained of nausea and vomiting so we reduced the dose to
5mg/d with good tolerance after that moment. Six months later
her depressive mood had improved and her family remarked she
had a little more autonomy and more desire to do things.
Conclusions Vortioixetinemight be an effective and safe option in
elder peoplewho have cognitive disturbances due tomood disorder
and/or dementia, probably because of its procholinergic action.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV0769
The neutrophil and platelet to
lymphocyte ratios in people with
subjective, mild cognitive impairment
and early Alzheimer’s disease
T. Kalelioglu ∗ Yuruyen Gultekin Yavuzer
Y. Ozturk Kurt opcu oventas Emul
1 Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital
for Psychiatry, Psychiatry, Istanbul, Turkey
2 Cerrahpasa faculty of medicine, Geriatric Medicine, Istanbul, Turkey
3 Cerrahpasa faculty of medicine, Psychiatry, Istanbul, Turkey
4 Cerrahpasa faculty of medicine, Medical Student, Istanbul, Turkey
∗ Corresponding author.
Background In this study we aimed to explore the role of inflam-
mation in subjects with mild Alzheimer dementia (AD), mild
cognitive impairment (MCI) and subjective cognitive decline (SCD)
via newpotential inflammationmarkers of Neutrophil-lymphocyte
ratio (NLR) and Platelet-lymphocyte ratio (PLR). NLR and PLR are
useful and cost-effective biomarkers, showing peripheral systemic
inflammation, were previously shown in neuropsychiatric disor-
ders
Methods In screening phase the patients were assessed with
mini-mental state examination, clinical dementia rating scale
(CDR), geriatric depression scale (GDS) and Hachinski Ischemic
Scale (HIS) after unstructured psychiatric interview according to
diagnostic and statistical manual of mental disorder, Text Revised
(DSM-IV, TR). Spectrum of cognitive decline includes 31 patients
with mild Alzheimer’s disease, 30 subjects with mild cogni-
tive impairment, 31 individuals with subjective cognitive decline.
Thirty-one healthy controls enrolled to the study.
Results NLR value of patients with AD was 2.38 ±0.81, subjects
with MCI was 2.48 ±1.19, SCD group was 2.24 ± 1.11 and con-
trol group was 1.85 ±0.80. NLR was significantly higher in AD
and MCI groups when compared with control group (P = 0.006,
P = 0.03, respectively). Platelet-lymphocyte ratiowas not correlated
with cognitive impairment. Neutrophil counts were indifferent
when comparing either of groups. Lymphocyte levels were signif-
icantly lower in each of cognitive decline groups when compared
to healthy controls.
Conclusion The present findings suggest that systemic inflamma-
tion may have a role in developing Alzheimer’s Disease.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Reference
[1] Kuyumcu ME, Yesil Y, Oztürk ZA, et al. The evaluation of
neutrophil-lymphocyte ratio in Alzheimer’s disease. Dement
Geriatr Cogn Disord 2012;34(2):69–74.
EV0770
Association between the use of
benzodiazepines and the occurrence
of acute angle-closure glaucoma in
the elderly: A population-based study
B. Kang , M.Y. Park , E. Lee , C. Kim , K. Namkoong ,
W.J. Kim ∗
1 Myongji Hospital Seonam University, Department of Psychiatry,
Goyang, Republic of Korea
2 Korea Institute of Oriental Medicine, Mibyeong Research Center,
Daejeon, Republic of Korea
3 Yonsei University College of Medicine, Department of Psychiatry,
Seoul, Republic of Korea
4 Yonsei University College of Medicine, Department of Preventive
Medicine, Seoul, Republic of Korea
∗ Corresponding author.
Introduction Acute angle-closure glaucoma (AACG) is an oph-
thalmic emergency, accompanied with severe eye pain, headache,
and visual changes because of acute intraocular pressure eleva-
tion. Among psychotropic drugs, several antidepressants, typical
antipsychotics with strong anticholinergic effects, and topiramate
have been known to increase a possibility of AACG. Benzodi-
azepines have been used widely in the treatment of mental and
physical illnesses regardless of age or indication. Since benzodi-
azepines have some anticholinergic properties and affect pupillae
muscles, their use could be theoretically a risk factor for AACG.
However, it is unclear whether benzodiazepines actually increase
the risk of AACG. To our knowledge, there was no population-based
study on the risk of benzodiazepines to the occurrence of AACG.
Objectives/aims To know whether benzodiazepines increase the
risk of AACG in a geriatric population.
Methods We will perform a case-control study using a geriatric
cohort from the National Health Insurance database. Case subjects
will be defined as cases diagnosed with AACG confirmed by the
claim data of laser iridotomy, which is the definitive treatment of
AACG. The controls, which were not diagnosed with AACG, will be
matched with case subjects according to similar age, sex, and the
scores of the Charlson comorbidity index.
Results The data handling and statistical analyses will be exe-
cuted in autumn and winter 2016.
Conclusions Any preliminary findings of this study will be pre-
sented at the EPA 2017. We will discuss the importance of a
pharmaco-epidemiological study in the geriatric research.